Pharmacovigilance Market to exceed $8bn by 2024

The research report Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract outsourcing) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Spain, Italy, France, China, Japan, India, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Qatar), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024 by Global Market Insights, Inc. says Pharmacovigilance Market will generate a revenue of more than USD 8 billion by 2024.Pharmacovigilance market is trending toward a remarkable growth path, owing to the presence of global organizations such as WHO, that undertake the responsibility to monitor the safety and effects of licensed drugs. Stringent government rules pertaining to the approval of drugs and their safety will also influence pharmacovigilance industry share considerably.

Request for a sample of this research report @ https://www.fractovia.org/request-sample/388

Contract outsourcing and in-house are the primary end user segments of pharmacovigilance market. Contract outsourcing segment accounted for more than 50% of market share in 2015, and is anticipated to collect a revenue of more than USD 4.8 billion by 2024. The surging adoption of outsourcing pharmacovigilance services by most of the industry giants to reduce the capital investment will augment the industry growth significantly.

Based on the clinical trial trends, pharmacovigilance industry is mainly divided into phase I, preclinical, phase II, phase III, and phase IV. Phase IV clinical trial was worth USD 2.4 billion in 2015 and will record an annual growth rate of 10.9% over the coming years of 2016 to 2024, primarily driven by rising concerns among the public regarding the safety and adverse effects of drug events. Phase III clinical trial generated a revenue of more than USD 492 million in 2015 and is predicted to cross a revenue collection of USD 1,254 million by 2024. The growth can be attributed to the increasing requirement to monitor drug safety and calculate usefulness of the drug depending on the risk-benefit ratio.

Browse key industry insights spread across 111 pages with 66 market data tables & 6 figures & charts from the report Pharmacovigilance Market in detail along with the table of contents:

https://www.fractovia.org/news/industry-research-report/pharmacovigilance-market

Given below is the regional analysis of pharmacovigilance market over 2016 to 2024:

Europe pharmacovigilance industry was worth USD 793 million in 2015 and will collect a revenue of USD 1.8 billion by 2024, with an annual growth rate of 9.9% over the coming seven years. The growth can be attributed to the surging requirement for personalized medicines.

Asia Pacific pharmacovigilance market collected a revenue of USD 835 million in 2015 and will surpass a revenue collection of USD 2.4 billion by 2024, owing to the implementation of stringent health care norms along with the presence of a huge patient base across this region.

U.S. pharmacovigilance industry share will register a CAGR of 10.7% over the period of 2016 to 2024. Supportive governmental regulations regarding drug approval coupled with the rising awareness pertaining to the safety of drugs among patients will favor the industry demand.

Many of the market players are willing to sign strategic partnerships with contract research organizations to provide customized services. The key participants in pharmacovigilance market are Accenture, Covance, Boehringer Ingelheim, PAREXEL, Bristol-Myers Squibb, United BioSource Corporation, Cognizant Technology Solutions Corporation, Quintiles, and ICON plc.

Make an inquiry for buying this report @ https://www.fractovia.org/request-purchase/388

Table of Content of Pharmacovigilance Market:

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.1.1. Initial data exploration

1.1.2. Statistical modeling and forecast

1.1.3. Industry insights and validation

1.1.4. Research scope and assumptions

1.2. Data Sources

1.2.1. Primary Sources

1.2.2. Secondary Sources

Chapter 2. Executive Summary

2.1. Pharmacovigilance industry 3600 synopsis, 2012 – 2024

2.1.1. Business trends

2.1.2. End user trends

2.1.3. Regional trends

Chapter 3. Pharmacovigilance Industry Insights

3.1. Industry segmentation

3.2. Industry size and forecast, 2012 – 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Increase in adoption rate of outsourcing services

3.3.1.2. Increasing consumption of drugs

3.3.1.3. Rise in adverse drug reactions (ADR) and drug toxicity

3.3.2. Industry pitfalls & challenges

3.3.2.1. Dearth of availability of skilled personnel

3.3.2.2. High risk associated with data security

3.4. Growth potential analysis

3.4.1. New business models

3.5. Porter’s analysis

3.6. Regulatory Landscape

3.7. Pharmacovigilance Reporting system

3.8. Company market share analysis, 2015

3.8.1. Strategy dashboard

3.9. PESTEL analysis

About Fractovia.org:

Fractovia.org is one of India’s leading in-house and free news portal. It is fully automated, and operates on a constant premise, interfacing with news sites and offering redesigned breaking features to readers across the globe. Our mission is to offer individuals opportunities for connections with news writers and distributors which they can pursue. We operate by mapping articles pertaining to breaking news, constantly and progressively, against a pre-determined word-based theme, offering important connections to readers and clients, as well as distributors.

Contact Us:

Arun Hegde
Corporate Sales, USA
Fractovia.org
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@fractovia.org
Website: https://www.fractovia.org
Connect with us:Facebook|Twitter

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: